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Autoimmune	diseases	develop	in	approximately	5%	of	humans.	They	can	arise	when	self-tolerance	checkpoints	
of	the	immune	system	are	bypassed	as	a	consequence	of	inherited	mutations	of	key	genes	involved	in	lympho-
cyte	activation,	survival,	or	death.	For	example,	autoimmune	lymphoproliferative	syndrome	(ALPS)	results	
from	defects	in	self-tolerance	checkpoints	as	a	consequence	of	mutations	in	the	death	receptor–encoding	gene	
TNF	receptor	superfamily,	member	6	(TNFRSF6;	also	known	as	FAS).	However,	some	mutation	carriers	remain	
asymptomatic	throughout	life.	We	have	now	demonstrated	in	7	ALPS	patients	that	the	disease	develops	as	a	
consequence	of	an	inherited	TNFRSF6	heterozygous	mutation	combined	with	a	somatic	genetic	event	in	the	
second	TNFRSF6	allele.	Analysis	of	the	patients’	CD4–CD8–	(double	negative)	T	cells	—	accumulation	of	which	
is	a	hallmark	of	ALPS	—	revealed	that	in	these	cells,	3	patients	had	somatic	mutations	in	their	second	TNFRSF6	
allele,	while	4	patients	had	loss	of	heterozygosity	by	telomeric	uniparental	disomy	of	chromosome	10.	This	
observation	provides	the	molecular	bases	of	a	nonmalignant	autoimmune	disease	development	in	humans	
and	may	shed	light	on	the	mechanism	underlying	the	occurrence	of	other	autoimmune	diseases.
Introduction
Autoimmune lymphoproliferative syndrome (ALPS, also known 
as lymphoproliferative syndrome with autoimmunity or Canale-
Smith syndrome) (1) is a human disease characterized by benign 
lymphoproliferation (splenomegaly and/or diffuse lymphadenop-
athy), and elevated serum immunoglobulins (IgG and IgA), plasma 
IL-10 levels (2, 3), and FAS-L levels. (4), accumulation in the blood 
and lymphoid organs of CD4–CD8–TCRαβ+ T cells (also referred 
to as double-negative [DN] T cells), susceptibility to malignant 
conditions (5), and autoimmune manifestations (6, 7).
Mutations in the TNF receptor superfamily, member 6 (TNFRSF6) 
gene (encoding FAS, also known as the CD95 receptor) are the 
most common cause of ALPS (8, 9). Patients carrying a homozy-
gous TNFRSF6 mutation have an early-onset severe phenotype, 
whereas subjects with heterozygous TNFRSF6 mutations present 
ALPS of variable intensity. T cells from patients with homozygous 
or heterozygous TNFRSF6 mutations, respectively, exhibit a com-
plete or partial functional impairment in an in vitro FAS-induced 
apoptosis assay. Moreover, somatic heterozygous mutations in 
TNFRSF6 in patients with a clinical ALPS phenotype were recently 
described (10, 11). In our experimental conditions, activated T cells 
showed normal sensitivity to FAS-induced apoptosis in vitro (11). 
The inability to detect an apoptosis defect was due to spontane-
ous in vitro apoptosis of the mutant T cells. However, more than 
80% of these patients’ DN T cells were mutated. These patients dis-
played mosaic expression of a somatic TNFRSF6 mutation, which 
provided the affected cells a selective advantage and accounted for 
the observed lymphoproliferation and autoimmunity.
However, heterozygous germline TNFRSF6 mutations are not 
always associated with clinical expression (partial clinical pen-
etrance), since some mutation-positive relatives (MPRs) remain 
asymptomatic despite an in vitro FAS-induced apoptosis impair-
ment on their T cells. This observation led us to postulate that a 
second event is necessary for disease expression in patients with 
TNFRSF6 mutations when an incomplete penetrance is observed. 
Here, we report that the combination of a germline TNFRSF6 
mutation and a somatic event impairing the second TNFRSF6 
allele can account for the onset of clinical phenotype in ALPS.
Results
Biological characteristics of the 7 ALPS patients and their asymptomatic 
relatives. Within the cohort of ALPS patients with heterozygous 
TNFRSF6 mutation studied in our institution (n = 87), 16% (n = 14) 
of the germline mutations affected the extracellular domain (ECD) 
of TNFRSF6. The clinical penetrance has been found to be much 
lower for heterozygous ECD mutations (30% of carriers developed 
ALPS) than for heterozygous intracellular domain (ICD) mutations 
(80% of carriers developed ALPS) (12, 13). This observation suggests 
that additional events are necessary for ALPS disease expression in 
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carriers of TNFRSF6 mutations with incomplete clinical penetrance. 
In order to search for these additional events, we analyzed the avail-
able T cells from 7 patients with the typical clinical symptoms of 
ALPS associated with monoallelic mutations affecting the ECD of 
TNFRSF6 (Table 1) and compared with asymptomatic family car-
riers in 4 cases. We first quantified ALPS markers: the percentage 
of DN T cells, plasma FAS-L, and IL-10 concentrations (2, 4, 14) 
(Figure 1A). In strict agreement with the clinical phenotype, all 
7 patients presented markedly elevated numbers of DN T cells and 
plasma FAS-L and IL-10 concentrations, whereas their asymptom-
atic MPRs carrying the same TNFRSF6 mutations exhibited normal 
DN T cell percentages and plasma IL-10 concentration and little or 
no increase in the plasma FAS-L concentration.
For all 7 patients, FAS-mediated T cell apoptosis was lower than 
for controls (Figure 1A). When simultaneously tested, we found 
that FAS-mediated apoptosis of patients’ T cells and their asymp-
tomatic MPRs had similarly low apoptosis levels; this contrasted 
with the results for nonmutated relatives (Figure 1A). Since the 
magnitude of the FAS-mediated apoptosis defect was similar in 
symptomatic and asymptomatic carriers of TNFRSF6 mutations, 
we postulated that any additional causative events did not directly 
have an impact on the FAS-induced apoptosis as assayed in 
vitro. This result was reminiscent of ALPS cases carrying somatic 
TNFRSF6 mutations but which were associated with normal FAS-
mediated T cell apoptosis in vitro (11).
Somatic mutations of TNFRSF6 in 3 patients with heterozygous germline 
mutations. Based on the literature description of ALPS sufferers carry-
ing a somatic TNFRSF6 mutation, which was predominantly found 
in DN T cells, we sequenced the TNFRSF6 gene in sorted DN T cells 
from each of the 7 patients. In addition to the previously identi-
fied germline TNFRSF6 mutation, we found a second heterozygous 
TNFRSF6 mutation in the DN T cells from patients 1, 2, and 3 (Fig-
ure 1B). In patient 1, a base insertion in exon 9 had created a prema-
ture stop codon at position 280. In patient 2, a nonsense mutation 
was found in exon 2 (G34X). In patient 3, a missence mutation was 
found in exon 9 (A237P). These somatic heterozygous TNFRSF6 
mutations were present in the second allele, since the cloned PCR 
products from cDNA amplified from these patients’ DN T cells 
exhibited only 1 of the 2 TNFRSF6 mutations (data not shown).
The proportion of cells carrying the somatic mutation was estab-
lished in several lineages for patients 1 and 2. In patient 1, the 
second mutation was found only in DN T cells and not in either 
single-positive T cells or epithelial cells (sensitivity threshold: 2.5% 
of cells) (Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI43752DS1). It was there-
fore impossible to determine at which stage of lymphocyte differen-
tiation the mutation had occurred. In patient 2, the mutation was 
found in 7%–35% of T cells, B cells, NK cells, and monocytes but also 
in buccal epithelial cells — indicating that the somatic mutation 
had occurred very early in embryogenesis. In the other 4 patients, 
TNFRSF6 sequencing did not highlight any second heterozygous 
mutation but revealed only the mutated allele in DN T cells (not 
shown), suggesting a somatic loss of the wild-type allele.
Loss of the wild-type TNFRSF6 allele in 4 patients. In order to identify 
the molecular basis of the loss of the wild-type allele in DN T cells 
from patients 4 to 7, we checked for single-nucleotide polymor-
phisms at the TNFRSF6 locus in DNA from DN T cells and from 
CD4+ T cells. In all 4 patients, DNA from the CD4+ T cells dis-
played heterozygous polymorphic microsatellite markers, whereas 
DNA from the DN T cells displayed homozygous markers (Figure 
2A). We then used serial microsatellite typing along chromosome 
10q in CD4+ T cell and DN T cell DNA to determine the location 
of the mutations. For patients 5 and 6, we honed in on a centro-
meric breakpoint region at about 1.3 kb upstream of the TNFRSF6 
locus (Figure 2A). Loss of heterozygosity (LOH) was observed 
down to the more distal telomeric marker, indicating that about 
45 Mb of parental DNA was missing. The conserved heterozygos-
ity observed in the CD4+ T cells suggested that very few (if any) 
of these cells carried the same chromosome aberration. Our data 
indicated that DN T cells exhibited telomeric uniparental disomy 
(UPD) or partial loss of the long arm of chromosome 10. The same 
analysis performed on the DN T cells from patient 4 and patient 7 
also revealed a mosaic LOH encompassing 60 Mb or more, respec-
tively (Figure 2A). This phenomenon was not observed in DN T 
cells from 3 ALPS patients carrying ICD mutations of TNFRSF6 
with incomplete clinical penetrance or from healthy carriers from 
families 1 to 4 (data not shown). Array-based comparative genom-
ic hybridization in patients 4, 6, and 7 (Figure 2B) and FISH in 
Table 1
Clinical features of 7 ALPS-FAS patients
	 P1	 P2	 P3	 P4	 P5	 P6	 P7
Germline mutation Ex 5: L159fs X186 Ex4:E116G Ex6: deletion Ex4:R121fs X159 Ex3: C107Y Ex3: C104G Ex5: C157X
Age (yr) 15 18 16 28 21 22 47
Age at onset (yr) 5 0.25 2 3 10 11 24
Splenomegaly +++ +++ +++ – ++ +++ ++
Lymphadenopathy +++ +++ ++ – ++ +++ ++
Autoimmunity: clinical None None Neutropenia  ITP  Arthritis None AIHA
  features   ITP AIHA Glomerulonephritis
Autoantibodies (anti-) None None Polynuclear Nuclear antigen  Nuclear antigen None Erythrocytes
    platelets
IgG (g/l)A 15.9 22.9–34.7 13.8 14.9 12.4–17.9 19.6–35 15.7
IgA (g/l)B 3.7 5.82–7.9 1.38 9 2.83–4.55 4.9–8.8 4.53
IgM (g/l)C 0.34 0.35 1.08 0.4 0.3–0.39 0.62–0.83 0.28
AControl values, 9.2–14.8 g/l. BControl values, 1.42–2.62 g/l. CControl values, 0.88–1.84 g/l. +, enlargement of the spleen not exceeding half the distance 
between costal margin and umbilical line and/or a lymph node diameter of between 1 and 2 centimeters; ++, enlargement of the spleen below half distance 
between the costal margin and umbilicus and/or a lymph node diameter of between 3 and 5 centimeters; +++, enlargement of the spleen further down the 
umbilicus and/or a lymph node diameter exceeding 5 centimeter or in clumps; ITP, immune thrombocytopenia; AIHA, autoimmune hemolytic anemia.
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patients 6 and 7 (data not shown) confirmed the LOH and con-
servation of the same gene copy number. The size of the chromo-
somal segment affected by the LOH in patient 4 was about 75 Mb. 
These results demonstrate that (a) the wild-type allele had been 
lost and (b) the mutated allele had been duplicated from the esti-
mated breakpoint down to the end of chromosome 10.
Measurement of FAS expression in cells with 2 disrupted TNFRSF6 
alleles. In order to determine the impact of these additional 
TNFRSF6 mutations or chromosome aberration, we analyzed 
FAS protein expression in CD4, CD8, and DN T cells from the 7 
patients, 3 asymptomatic MPRs (patient 2’s mother, patient 3’s 
father, and patient 4’s father), and 5 healthy controls (Figure 3). 
First, we found that FAS expression in single-positive (CD4 or 
CD8) T cells was slightly lower than control values in all patients 
or relatives carrying a low-penetrance ECD TNFRSF6 mutation 
(except for patient 1); this suggests that the germline TNFRSF6 
mutation in allele 1 led to defective expression in patients 2 to 7. 
Further analysis indicated that the great majority of these patients’ 
DN T cells did not express FAS. Interestingly, DN T cells from 
patients 2, 3, and 4 expressed less FAS than those from patient 2’s 
mother, patient 3’s father, and patient 4’s father, respectively 
(Figure 3, A and B). The low FAS expression in these cells was not 
due to an activation defect, since they expressed high amounts of 
human leukocyte antigen class II molecules (Supplemental Fig-
ure 1). Strikingly, no decrease of FAS expression was observed in 
3 patients carrying germline ICD TNFRSF6 mutations associated 
with low penetrance. Accordingly, no somatic mutation has been 
detected in these patients. These results indicated that the somatic 
event in DN T cells is mostly associated with reduced FAS expres-
sion via loss of the wild-type TNFRSF6 allele.
Discussion
Severe ALPS always occurs when both TNFRSF6 alleles are mutated 
in the germline in humans (9, 15, 16) or mice (17). In contrast, if the 
FAS defect is partial (as in the case of a heterozygous mutation, for 
example), the human disease develops in 70% of carriers (13). The 
partial clinical penetrance of heterozygous TNFRSF6 mutations in 
ALPS suggests that in addition to the germline TNFRSF6 mutation, a 
“second hit” is required for disease onset. Here, we identified somat-
ic genetic events affecting the second TNFRSF6 allele in 7 patients 
carrying a germline heterozygous mutation with low clinical pen-
etrance. In these patients, a small proportion of lymphocytes lacked 
functional FAS — leading to uncontrolled proliferation and autoim-
munity. Missence or nonsense somatic mutations were identified in 
3 patients, whereas somatic UPD (duplication of the mutant allele 
with loss of the wild-type allele) were found in the other 4 patients.
Figure 1
Family tree of 7 ALPS patients with 
germline heterozygous TNFSFR6 
mutations and additional somatic muta-
tions in patients 1, 2, and 3. (A) Family 
trees of 7 ALPS patients with a germ-
line ECD TNFRSF6 mutation. Asymp-
tomatic mutated relatives are indicated 
by vertical gray bars. Subjects with 
ALPS are marked in black (arrows). 
The range of values determined for the 
4 ALPS markers, i.e., apoptosis of acti-
vated T cells (control > 75%), plasma 
IL-10 concentration (control < 20 pg/
ml), plasma FAS-L concentration (con-
trol < 0.2 ng/ml), and the percentage of 
DN T cells (< 2% of TCRαβ cells) are 
shown for these patients and their rela-
tives. Apoptosis values depicted in bold 
were obtained in an assay performed 
at the same time for patients’ cells 
and relatives’ cells. P1, patient 1. (B) 
Localization of the 2 mutations in the 
TNFRSF6 alleles (9 exons) for patients 
1, 2, and 3. The oblique gray bars in 
exon 6 and the dark section in exon 9 
represent the transmembrane domain 
and the death domain, respectively.
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Interestingly, we identified somatic events in 7 patients carrying 
germline heterozygous TNFRSF6 mutations affecting the ECD of 
FAS. The latter are known to frequently induce a loss of FAS expres-
sion at the cell membrane and therefore haploinsufficiency (18). 
This was confirmed by analyzing cells from the MPRs, in which 
the only germline mutation was present. Expression of half the 
normal level of FAS receptor is sufficient to trigger apoptosis and 
might preclude the onset of ALPS and account for the low clinical 
penetrance seen with ECD TNFRSF6 mutations. The additional 
somatic event led to a clear, profound expression defect in a small 
proportion of single-positive T cells and in the majority of DN T 
cells from all but 1 patient. In this latter case, patient 1 carried 2 
missence mutations (one germline and one somatic), which were 
predicted to be nonfunctional. The subsequent in vivo functional 
defect could thus be the consequence of either the lack of FAS 
expression at the cell membrane or the lack of apoptosis signal. 
Figure 2
LOH on chromosome 10 of DN T cells from 4 patients carrying germline heterozygous TNFRSF6 mutations. (A) Polymorphic markers used for 
LOH characterization. Each allele is represented by the symbol I. Horizontal bars indicate the upstream LOH region in DN T cells. NI, not informa-
tive. (B) An array comparative genome hybridization profile of chromosome 10, showing the LOH (phenotype A/A or B/B but no heterozygosity 
A/B) and the stable allele copy number (the numbers above the schema depicted the allele copy number: 2 copies along the entire chromosome) 
that are characteristic of UPD (duplication of the mutant allele with loss of the wild-type allele) in DN T cells of patients 4, 6, and 7. The arrowhead 
indicates the upstream site of LOH.
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Figure 3
Impact of TNFRSF6 mutations on FAS protein expression by lym-
phocyte subsets. FAS expression by CD4, CD8, and DN T cells was 
determined by FACS analysis (A) for patients 1 to 3 carrying a germ-
line TNFRSF6 mutation and a somatic TNFRSF6 mutation in the sec-
ond allele; (B) for patients 4 to 7 carrying a germline heterozygous 
TNFRSF6 mutation and exhibiting LOH on the second allele; and (C) 
for 3 ALPS patients carrying germline ICD TNFRSF6 mutations. Analy-
sis was also performed for 3 MPRs (patient 2’s mother, patient 3’s 
father, and patient 4’s father). Patients 2 and patient 4 to 6 and their 
respective MPRs were analyzed in parallel in the same experiment, 
using an ARIA II cytometer. Patient 1, patient 3, and all patients with 
ICD mutations were processed in distinct experiments in parallel with 
different healthy controls, using an ARIA II cytometer. Numbers on 
histograms indicate the percentage of cells in the depicted FAS-nega-
tive gates, and numbers in bold type indicate the mean fluorescence 
of FAS intensity in the whole population.
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This could result from a lack of multimerization of the receptor or 
the lack of death-inducing signaling complex (DISC) recruitment 
by the residual FAS molecules. Consequently, the double-mutant 
lymphocytes could not be killed by FAS-L. A similar situation 
has been observed in patients carrying inherited homozygous or 
compound heterozygous mutations (9, 15). The lymphoprolifera-
tion observed in the latter patients indicated that a complete FAS 
defect led to uncontrolled proliferation of T and (to a lesser extent) 
B cells. In contrast, most missence mutations affecting the ICD 
of TNFRSF6 are known to exert a transdominant negative effect, 
since the mutant protein is likely to trimerize with wild-type FAS. 
Assuming that efficient DISC formation and subsequent apopto-
sis triggering require wild-type FAS trimers only, it was estimated 
that 1 out of 8 trimers would be functional. The ensuing apoptosis 
defect may be sufficient to account for the onset of ALPS. Accord-
ingly, the clinical penetrance of the ICD missence TNFRSF6 muta-
tion was complete in most families (19). Moreover, no additional 
defect in the TNFRSF6 gene could be found in 3 tested patients 
with ICD mutations. It is noteworthy that previously described 
cases of ALPS caused by somatic heterozygous mutations (10, 11) 
were mostly associated with ICD TNFRSF6 mutations. This obser-
vation suggested that somatic ICD TNFRSF6 mutations markedly 
impair FAS function and provide the mutant cells with a selective 
advantage in vivo. Moreover, the patients carrying somatic ICD 
mutations developed clinical disease, despite the low proportion 
(10%–20%) of mutant lymphocytes. A similar picture was seen in 
our current cases, since the somatic events were seen in a minor 
fraction of single-positive T cells and in a major fraction of DN 
T cells. This observation supports the concept whereby the sec-
ond hit (somatic mutation or UPD) together with the germline 
ECD-mutated TNFRSF6 gene, profoundly impair FAS function 
and provide the double-mutant T cells with a selective advantage 
in vivo. The double-mutant cells died spontaneously in vitro and 
so could not be tested. Consequently, in vitro expansion of the 
patients’ T cells led to accumulation of the germline mutants only. 
Accordingly, the magnitude of the FAS-induced apoptosis defect 
was similar in T cells from the patients and their asymptomatic 
mutated relatives, respectively.
The combination of germline and somatic mutations in the same 
gene has been reported in cancers with a hereditary predisposi-
tion, such as retinoblastoma (20). Similarly, missence mutations 
of TNFRSF6 outside the death domain are associated with LOH 
in non-Hodgkin lymphomas (21). The LOH observed in 4 of our 
patients with germline TNFRSF6 ECD mutations resulted from loss 
of the wild-type allele and concomitant duplication of the mutant 
one, i.e., telomeric UPD. This type of mechanism is usually observed 
in genetic disorders of development, where it can be involved in 
trisomy or monosomy rescue during embryonic development 
(22). The telomeric UPD observed in our ALPS cases might reflect 
a recombination hotspot on the 10q chromosome (as described 
in the 10q syndrome; ref. 23), but more likely reflect the selective 
advantage provided by the resulting homozygous TNFRSF6 muta-
tions. These events may occur during embryogenesis (patient 2) or 
later in life (since the onset of clinical manifestations was delayed in 
patients 5, 6, and 7). Implication of modifier genes in the onset of 
ALPS was previously postulated. The present findings highlight the 
role of somatic events affecting the second TNFRSF6 allele as modi-
fier in ALPS expression. However, we could not strictly exclude that 
these somatic FAS events result from other, yet undefined, germline 
mutation in the actual “ modifier” genes.
Lymphocyte homeostasis and self tolerance are maintained by 
several checkpoints, including antigen receptor editing, modula-
tion, anergy, and central or peripheral clonal deletion of self-reactive 
lymphocytes (24). Variants of proteins involved in cell activation, 
survival, proliferation, and death may contribute to the emergence 
of autoimmunity (25). For instance, variants of the genes for HLA 
molecules (selecting for self-reactive lymphocytes), PTPN22 (regu-
lating Antigen receptor signaling), and CTLA-4 (inhibiting T cell 
proliferation) are risk factors in the occurrence of various autoim-
mune diseases. It has been postulated that in view of the moderate 
functional impact of these variants, additional events are required to 
bypass the tolerance checkpoints. This model accounts for the rela-
tively long time to onset of autoimmune disease in most patients. 
Our identification of a combined germline TNFRSF6 mutation 
(with incomplete clinical penetrance) and a somatic event affecting 
the second TNFRSF6 allele now demonstrates that a hit on each 
of the 2 alleles of the same gene can lead to lymphoproliferation 
and autoimmunity. On the basis of this observation, one can pos-
tulate that combinations of gene variants and somatic mutations 
in genes involved in cell death (such as Bim, Bid, or caspases) or in 
the regulation of cell proliferation (such as PD-1 or CTLA-4) could 
be involved in the emergence of autoimmune disease via the selec-
tion of self-reactive T and B lymphocytes. This hypothesis could be 
tested in models of autoimmunity in which self-reactive T and/or 
B cell clones can be identified. Somatic mutations occur relatively 
frequently (i.e., 10–6 per gene per cell division) (26). Consequently, 
in the context of the high-rate cell division seen in both lymphoid 
precursors and mature lymphocytes, a role for somatic mutations 
in triggering autoimmune disease onset should be considered.
In conclusion, our present findings validate the “2-hit” hypoth-
esis in the setting of a nonmalignant disease and highlight the pos-
sible impact of somatic mutations on the onset of other autoim-
mune diseases in humans.
Methods
Study population. Seven patients presenting with typical ALPS manifesta-
tions (including autoimmune manifestations in 3 cases) and carrying 
germline heterozygous TNFRSF6 mutations affecting the ECD of the 
protein were enrolled in this study (Table 1). Relatives of patients 1 to 5 
(including 7 asymptomatic MPRs) as well as 3 patients carrying a germline 
heterozygous ICD TNFRSF6 mutation (D269fsX279; G253D; K296fsX279) 
were also investigated as controls. The study protocol was approved by 
the local investigational review board (CPP ile de France II, Ministry of 
Research, Paris France). Informed consent was obtained from the patients 
or their families prior to study entry.
Immunofluorescence and cell sorting. Using flow cytometry, the percentage 
of DN T cells was defined as the percentage of TCR-αβ–positive cells that 
lacked CD4 and CD8 expression. Thawed peripheral blood mononuclear 
cells were incubated with a cocktail of 2.5 μl of anti–TCR PAN α/β PC5 
antibody (IP26A; Immunotech; Beckman Coulter), 5 μl of anti–CD4-
APC antibody (SK3), 10 μl of anti–CD8-V500 antibody (RPAT8), 10 μl of 
anti–CD95-PE antibody (DX2), and 10 μl of anti–HLA-DP-DQ-DR-FITC 
(TU39) (BD Biosciences) per 4 million cells. Acquisition and cell sorting 
were performed with an ARIA I or ARIA II cytometer (BD Biosciences), and 
data were analyzed using Flowjo software (TreeStar Inc.).
Plasma IL-10 and FAS-ligand and apoptosis assays. Plasma IL-10 and FAS-
ligand levels and apoptosis were assayed as previously described (4).
Detection of TNFRSF6 mutations. DNA was isolated by proteinase K diges-
tion and phenol-chloroform extraction. Genomic DNA segments were 
amplified as previously described (11).
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DNA cloning. PCR products were cloned using TOPO TA cloning kit 
(Invitrogen) following the manufacturer’s instructions. The sequences 
of at least 80 clones were then determined by capillary electrophoresis 
using Applied Biosystems DNA sequencing kits and a 3130xl Genetic 
Analyzer (Applied Biosystems).
Genotype analysis. All analyzed microsatellite markers flanked the 
TNFRSF6 locus or genes located on the 10q chromosome. Primer sequenc-
es were retrieved from the Genome Database (http://www.ncbi.nlm.nih.
gov). FISH experiments were performed with BAC RP11-399O19 (a probe 
spanning the TNFRSF6 locus) as previously described (27). Analysis of copy 
number variations and LOH was performed using Whole-Genome Cytoge-
netics 2.7M DNA chips (Affymetrix). The results were visualized using the 
Chromosome Analysis Suite (version 1.0.1; Affymetrix).
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